You just read:

Head-to-head study demonstrating Gilotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Apr 13, 2016, 08:00 ET